In particular, expression of CD44, a classical marker associated with epithelial-to-mesenchymal transition and poor prognosis of PDAC progression and metastasis (41, 42), was found associated with Tumor 3 (3.6%, range 0.2-9.0% per PDAC), Tumor 4 (2.2%, range 0-10.0% per PDAC) and Tumor 7 subtypes (Figures 2A–C). Here, CD44 is linked to neoplasm.